Silencing of PHD1 has been shown to prevent p53 activation upon chemotherapy in different CRC cell lines, thereby inhibiting DNA repair and favoring cell death (Deschoemaeker et al. 2015). This evidence concerns the gene EGLN2 and colorectal carcinoma.